Roche: positive safety data in haemophilia
(CercleFinance.com) - On Monday morning Roche announced the results of a second interim analysis of the Stasey Phase IIIb study, reinforcing the safety profile of Hemlibra (emicizumab) characterised in the Haven Phase III clinical program.
According to the Swiss pharmaceutical group, Hemlibra has been shown to be effective with no new safety signals identified in adult and adolescent haemophilia A patients with factor VIII inhibitors, consistent with previous safety observations.
The company adds that a separate analysis suggests that people on Hemlibra may undergo some minor surgery without additional preventive clotting therapy.
Copyright (c) 2020 CercleFinance.com. All rights reserved.